Careful use of science to advance the debate on the UK cancer drugs fund

JAMA

Volumn 311, Issue 1, 2014, Pages 25-26

  Lakdawalla, Darius N ^a   Jena, Anupam B ^b,c,d   Doctor, Jason N ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; COST BENEFIT ANALYSIS; DRUG INDUSTRY; ECONOMICS; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HUMAN; INSURANCE; NATIONAL HEALTH SERVICE; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; FINANCING, GOVERNMENT; GREAT BRITAIN; HEALTH POLICY; HUMANS; INSURANCE COVERAGE; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATE MEDICINE;

EID: 84891908847     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282839     Document Type: Note

References (8)

1. Sullivan R, Purushotham A. New £50 million cancer fund already intellectually bankrupt. Lancet. 2010;376 (9739):389.
2. Barnato AE, Herndon MB, Anthony DL, et al. Are regional variations in end-of-life care intensity explained by patient preferences?: a study of the US Medicare population. Med Care. 2007;45(5):386-393.
3. Linley WG, Hughes DA. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22(8):948-964.
4. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
5. Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood). 2012;31(4): 676-682.
6. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990;300(6737):1458-1460.
7. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol. 2008;26(23):3860-3866.
8. Verhoef LC, de Haan AF, van Daal WA. Risk attitude in gambles with years of life: empirical support for prospect theory. Med Decis Making. 1994;14(2):194-200.